Web Search powered by YAHOO! SEARCH
06.17.2009 6:21 pm

Mallinckrodt in licensing deal for Exalgo

St. Louis Post-Dispatch

Covidien’s Mallinckrodt Inc. unit based in Hazelwood has acquired the licensing rights to Exalgo, an extended release formulation of hydromorphone, from a unit of Neuromed Pharmaceuticals Ltd.

Exalgo, an opioid analgesic, is awaiting Food and Drug Administration approval. Financial terms of the deal…

  • Comments Off
  • Email this
02.07.2008 12:38 pm

Covidien sees rise in first-quarter sales

St. Louis Post-Dispatch

Covidien Ltd., which has 3,000 area employees in two Hazelwood-based business units operating as Mallinckrodt Inc., on Thursday reported a 9 percent gain in first-quarter net sales, to $2.3 billion from $2.1 billion a year ago. Higher volume sales and…

  • Comments (0)
  • Email this
02.06.2008 2:37 pm

Covidien unit faces federal inspection

St. Louis Post-Dispatch

Federal regulators are inspecting the Hazelwood-based Mallinckrodt unit of Covidien Inc. after learning of problems with generators it sold for use in nuclear medicine.

The Nuclear Regulatory Commission said Wednesday that the generators were producing doses containing a nuclear isotope, molybdenum-99, that should…

  • Comments (2)
  • Email this